CD274 and neoplasm: Efforts to further optimize TIL therapy for OC include combining TILs with IL-2 support to enhance T-cell survival post-infusion, integrating checkpoint inhibitors (e.g., PD-1 blockade) to counteract tumor-mediated immunosuppression, and improving patient selection criteria, such as identifying individuals with pre-existing TILs or PD-L1 expression, who may be more likely to benefit from therapy [132].